Skip to main content
. 2023 Jan 30;162(3):461–469. doi: 10.1007/s11060-023-04250-5

Table 2.

Essential and desirable criteria for the diagnosis of IDH-mutant gliomas

Tumor type Essential criteria Desirable criteria Additional altered genes
Astrocytoma, IDH-mutant Diffusely infiltrating glioma Astrocytic differentiation by morphology CDKN2A, CDKN2B, CDK4, CCND2, PDGFRA, MET, MYC, MYCN, RB1, PIK3R1, PIC3CA, others
IDH1/2 hotspot mutation TP53 mutation or strong nuclear expression of p53 in > 10% of tumor cells
ATRX loss or ATRX mutation OR exclusion of combined whole-arm deletions of 1p and 19q Methylation profile of astrocytoma, IDH-mutant
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted Diffusely infiltrating glioma Retained nuclear expression of ATRX CDKN2A, CDKN2B, CIC, FUBP1, NOTCH1
IDH1/2 hotspot mutation TERT promoter mutation
Combined whole-arm deletions of 1p and 19q DNA methylome profile of oligodendroglioma, IDH-mutant and 1p/19q-codeleted